Kymera Therapeutics (KYMR) PT Raised to $38 at Morgan Stanley
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/30/2026
- Nasdaq futures sink as Amazon, Intel intensify AI spending fears
- Amazon burns cash, Intel flags weak PC demand as AI boom's costs ripple across markets
- Bitcoin, cryptocurrency prices fall after Binance reports security issue
- Higher yields now hurting AI stock bull as bond markets police capex: BofA
- Oil set for fourth monthly gain as Hormuz tanker attack highlights supply risks
Tweet
Share
E-mailGet Alerts KYMR Hot Sheet
Price: $122.60 --0%
Rating Summary:
26 Buy, 4 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 7 | Down: 38 | New: 6
Rating Summary:
26 Buy, 4 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 7 | Down: 38 | New: 6
Join SI Premium – FREE
Morgan Stanley analyst Vikram Purohit raised the price target on Kymera Therapeutics (NASDAQ: KYMR) to $38.00 (from $37.00) while maintaining a Equalweight rating.
You May Also Be Interested In
- Kymera Therapeutics (KYMR) PT Raised to $150 at Truist Securities
- Kymera Therapeutics (KYMR) Misses Q3 EPS by 5c
- JB Hi-Fi Ltd (JBH:AU) PT Lowered to AUD80 at JPMorgan
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
